Search

Displaying results 1421 - 1430 of 10000 in total
  1. Drug

    Poliovirus type 3 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10797
    ApprovedInvestigational

    Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis

    Mixtures: VeroPol Injektionslösung in einer Fertigspritze, -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE
  2. Drug

    Streptococcus pneumoniae type 8 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10326
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche
  3. Drug

    Streptococcus pneumoniae type 10a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10329
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche
  4. Drug

    Streptococcus pneumoniae type 11a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10330
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche
  5. Drug

    Cocamidopropyl betaine

    go.drugbank.com/drugs/DB11350
    Approved

    It is a zwitterionic ammonium compound and fatty acid amide that contains a long hydrocarbon chain and a polar group at each end. … Cocamidopropyl betaine is used as a foam booster in shampoos, emulsifying agent, thickener, antistatic agent and rarely an antiseptic agent.

    Categories: Compounds used in a research, industrial, or household setting
  6. Target

    Succinate dehydrogenase cytochrome b560 subunit, mitochondrial

    go.drugbank.com/bio_entities/BE0002257
    TargetEnzymeHumans

    Membrane-anchoring subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to

    Synonyms: Succinate dehydrogenase complex subunit C
  7. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.

  8. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution … Dihydroergotamine is used as an abortive therapy for migraines.

    Synonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
  9. Drug

    Irinotecan

    go.drugbank.com/drugs/DB00762
    ApprovedInvestigational

    Both irinotecan and SN-38 mediate antitumor activity by forming a complex with topoisomerase I and blocking its enzymatic activity, thereby interfering with DNA synthesis. … [A263381] As an anticancer drug, irinotecan was first commercially available in Japan in 1994 to treat various cancers such as lung, cervical and ovarian cancer.

  10. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.

    Categories: Receptors, Prostaglandin E, EP2 Subtype, agonistsSynonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinate